Furthermore, different breast cancer subtypes have different tumor microenvironments; HR+ breast cancers, in contrast to triple-negative and HER2+ breast cancers, show lesser immune cell infiltration and a worse response to immune checkpoint blockade (76). This evidence concerns the gene ERBB2 and neoplasm.